Published in Vaccine Weekly, July 6th, 2005
The LSE listing decision reflects Introgen's ongoing discussions with potential international distribution partners, including European entities, as well as the expansion of its European investor base. In December 2004, Introgen placed shares with European institutions to increase its already significant European investor base. Introgen's first underwritten offering in 1997 was sold exclusively to European institutions.
In addition, the Company recently...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.